Time to Sell the Rally and Buy These 5% and Higher Blue-Chip Dividend Giants24/7 Wall Street • 06/30/25
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy LabelsBusiness Wire • 06/27/25
This Once Dominant Dividend Stock May Be About to Come Back to Life in July24/7 Wall Street • 06/26/25
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?Zacks Investment Research • 06/25/25
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?Zacks Investment Research • 06/20/25
Bristol Myers Squibb (BMY) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 06/16/25
Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)Business Wire • 06/16/25
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?Zacks Investment Research • 06/13/25
Dividend Harvesting Portfolio Week 223: $22,300 Allocated, $2,310.77 In Projected DividendsSeeking Alpha • 06/12/25
Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025Business Wire • 06/12/25
Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025Business Wire • 06/12/25
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/11/25
Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic ArthritisBusiness Wire • 06/11/25
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royaltiesGlobeNewsWire • 06/10/25